Medical and Economic Evaluation for Intermediate-risk Prostate Cancer

Inclusion Criteria: * age between 18 and 80 years; * life expectancy of greater than 10 years; * prostate adenocarcinoma histologically proven; * prostate cancer has to be of intermediate-risk based on at least one of the three following criteria: PSA between 10 ng/ml and 20 ng/ml, and/or a Gleason score of 7 and/or a T2B. Karnofsky performance status ≥ 60% and consequently performance status ECOG 0-2. * the patient has to be the beneficiary of the social security system (order n° 2006-477 from April 26th 2006); * the signed consent form. Exclusion Criteria: * PSA level \> 20; * Gleason \> 7; * clinical T3A or T3B or MRI (a simple suspicion/ doubt on the MRI regarding the T3A won't be an exclusion criterion); * prostate volume \> 60 cc; * pelvic lymph nodes involvement at dissection or imaging (ADP \> 1.5 cm); * concurrent hormone therapy; * the presence of distant metastasis (M1); * history of abdominal or pelvic irradiation; * history of prostate resection in the previous 6 months and/or not allowing the implantation of markers; * history of uncontrolled cancer and/or treated since less than 5 years (excepting the basal-cell carcinoma); * urinary discomfort with an IPSS (International Prostate Symptom Score) \> 15 (without alpha-blocking); * inflammatory bowel disorder such as ulcerative colitis or the Crohn's disease; * other undergoing study that may interfere with the present study; * patient under legal protection measure.